Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC includes a print copy delivered by postal mail and on-line access to electronic PDF copies of your subscribed issues.

Compounding with Biotechnology Products, Part 1: General Considerations

Author(s):  Allen Loyd V Jr

Issue:  Sep/Oct 2022 - Volume 26, Number 5
View All Articles in Issue

Abstract:  Biotechnology drugs involve any technique that uses living organisms in their production or modification. These biotechnology drugs are prepared using different techniques such as recombinant DNA technology monoclonal antibody technologies along with tissue cultures living cells and cell enzymes to make specific products. These new pharmaceuticals are utilized in the diagnosis treatment and prevention of disease but, because of the risk of clinically important and unusual and potentially harmful adverse effects produced, these agents require increased safety surveillance, and it is very important for pharmacists to participate in any adverse event reporting and monitoring program for these new products. The first biotechnology pharmaceuticals are proteins, but, eventually, an ever-increasing number of smaller molecules may be discovered through the previously mentioned methods and may become a mainstay in new pharmaceutical research and development in producing new drug products. Pharmacists involved in compounding must be aware of not only the biotechnology agent itself but especially of all of the different excipients that are required in order to produce a stable and safe preparation for patient use. Compounding involving these formulations should involve the simplest procedures and formulations as possible, maintaining sterility throughout the entire process. It is important to maintain a drug’s biologic activity up to the point of administration to the patient, and the pharmacist can assist in explaining the various factors involved in storage preparation and administration of the drugs to the patient. In the next issue of this two-part series, we will look at the formulations for a number of commercially available biotechnology products and the purpose of each of the ingredients and any uniqueness about their formulations.

Related Keywords: Loyd V. Allen Jr., PhD, RPh, biotechnology drugs, recombinant DNA technology, monoclonal antibody technology, tissue cultures, living cells, cell enzymes, adverse events, drug safety, biosimilars, follow-on biologics, biologic agents, polymerase chain reaction, PCR, gene therapy, nucleotide blockage, antisense nucleic acids, rDNA, protein drugs, stabilizers, filter loss, container sorption, protein structure, isoelectric point, molecular weight, solubility, stability, quality control, agitation, tissue penetration, absorption, immune reaction, drug delivery, nanoparticles, liposomes, targeted delivery, polymer-drug conjugates, pegylation, polyethylene glycol, encapsulation, nanomedicine, diagnostic products, patient education, chelating agents, antioxidants, preservatives, tonicity

Related Categories: STABILITIES, COMPATIBILITIES, TECHNOLOGY, QUALITY CONTROL, PATIENT EDUCATION, ADVERSE DRUG EVENTS, PROFESSIONAL ISSUES

Printer-Friendly Version




Download in electronic PDF format for $55

Related Articles from IJPC
Title (Click for Abstract / Details) Author Issue Page View/Buy
Compounding with Biotechnology Products, Part 1: General Considerations Allen Loyd V Jr Sep/Oct 2022 385-395 Buy
Rapid-Dissolve Technology: An Interview With Loyd V. Allen, Jr., PhD, RPh Allen Loyd V Jr Nov/Dec 2003 449-450 Buy
Compounding for the Effects of Weapons of Mass Destruction Sammarco Domenic A Jan/Feb 2003 10-15 View Sample
Wetting and/or Solubilizing Agents, Featured Excipient: Allen Loyd V Jr Jul/Aug 2001 310-312 Buy
Biotechnology, Nanotechnology, and Pharmacogenomics and Pharmaceutical Compounding, Part 2 Allen Loyd V Jul/Aug 2015 280-287 Buy
Infliximab 1% Ophthalmic Solution Allen Loyd V Jr Jan/Feb 2017 62 Buy
Biotechnology, Nanotechnology, and Pharmacogenomics and Pharmaceutical Compounding, Part 1 Allen Loyd V Jr Jan/Feb 2015 38-40 Buy
PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs Allen Loyd V Jr Sep/Oct 2017 356 Buy
Stability of Diazepam Enema Extemporaneous Formulation in Manzoni Base Lopalco Antonio, Lopedota Angela, Aurelio Fiorenza, la Forgia Flavia, Fontana Sergio, Franco Massimo, Denora Nunzio Sep/Oct 2021 427-430 Buy
Determining Whether a Substance is Legal to Compound with Under Section 503A of the FDCA Cabaleiro Joe Sep/Oct 2021 358-362 Buy